OYSTER POINT PHARMA, INC. (OYST) News

OYSTER POINT PHARMA, INC. (OYST): $4.42

0.09 (+2.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OYST to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter OYST News Items

OYST News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OYST News Highlights

  • OYST's 30 day story count now stands at 4.
  • Over the past 9 days, the trend for OYST's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about OYST are EYE.

Latest OYST News From Around the Web

Below are the latest news stories about Oyster Point Pharma Inc that investors may wish to consider to help them evaluate OYST as an investment opportunity.

Oyster Point Pharma, Inc. (OYST) Q4 2021 Earnings Call Transcript

This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com.

Yahoo | February 25, 2022

Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4’21, plus $5.4 Million Recognized from Ji Xing Pharmaceuticals (Ji Xing) License Agreement in Q4’21Over 5,500 TYRVAYA Prescriptions Filled; Prescriptions Written by Approximately 1,900 Unique Eye Care Professionals in November and December 2021$50 Million Drawn on Second Tranche from OrbiMed Royalty

Yahoo | February 24, 2022

Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express Scripts

One of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic and High-Performance Formularies, effective February 19, 2022. FDA Approved TYRVAYA Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021. TYRVAYA Nasal Spray became commercially available at U.S. pharmacies and for home delivery in November 2021. PRINCETON, N.J., Feb. 22, 2022 (GLOBE NEWSWIR

Yahoo | February 22, 2022

Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022

Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ETPRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after the market close. The announce

Yahoo | February 16, 2022

Mass General Brigham, Inc Buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Sells iShares ...

Investment company Mass General Brigham, Inc (Current Portfolio) buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Airbnb Inc, sells iShares Core S&P 500 ETF, iShares Core U.S.

Yahoo | January 20, 2022

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of its Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 90,800 shares of common stock to seven new employees, pursuant to the Oyster Po

Yahoo | January 4, 2022

Even after rising 24% this past week, Oyster Point Pharma (NASDAQ:OYST) shareholders are still down 12% over the past year

Oyster Point Pharma, Inc. ( NASDAQ:OYST ) shareholders will doubtless be very grateful to see the share price up 56% in...

Yahoo | December 24, 2021

Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the following upcoming investor conferences:

Intrado Digital Media | December 21, 2021

Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index

PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that Oyster Point Pharma will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20 th .

Intrado Digital Media | December 15, 2021

Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the Piper Sandler 33 rd Annual Healthcare Conference on Thursday, December 2, 2021. Presentations are available for registered attendees via the Piper Sandler conference site

Intrado Digital Media | November 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5347 seconds.